Drug Index


Mechanism :

It is an opioid analgesic used in the treatment of intractable pain and cyanotic spells. It is 25 times more potent than morphine and has a longer duration of action.

Indication :

  • Injection: Management of moderate to severe pain.
  • Sub lingual tablets: Treatment of opioid dependence.

Contraindications :

Hypersensitivity to buprenorphine or any of its components.

Dosing :

<2 years:
Safety and efficacy not established.
Management of mild to moderate pain:
2-12 years: 2-6 mcg/kg slow IV/IM every 4-6 hours.
>12 years (same as adults): 0.3 mg IV/IM every 6 hours. When given IV, administer slowly over 2 minutes; may be repeated once (up to 0.3 mg) if required 30-60 minutes after initial dose.

Adverse Effect :

Asthenia, chills, headache, infection, abdominal pain, back pain, withdrawal syndrome, dizziness, confusion, fatigue, nervousness, slurred speech, paresthesia, somnolence, tinnitus, tremor, coma, convulsions, elevated cerebrospinal fluid pressure, hypoventilation, cyanosis, constipation, diarrhea, nausea, vomiting, rash, hives, pruritus, bronchospasm, angioneurotic edema, anaphylactic shock, vasodilation, orthostatic hypotension, chest pain, sweating, blurred vision, conjunctivitis, amblyopia, and miosis, euphoria, depersonalization, depression, dreaming, psychosis, auditory and visual hallucinations, urinary retention.

Interaction :

CNS depressants: Increased CNS depression may occur in patients receiving concurrent CNS depressants (e.g., narcotic analgesics, general anesthetics, benzodiazepines, phenothiazines, tranquilizers, sedative/hypnotics, or alcohol)

Diazepam: Respiratory and cardiovascular collapse with concurrent use of diazepam.

Alvimopan: Increases levels of buprenorphine by receptor binding competition and its concurrent use is contraindicated.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function, but avoid very large doses
<10Reduce dose by 25–50% initially and increase as tolerated; avoid very large single doses Transdermal: Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDDialysed. Dose as in GFR<10 mL/ min
HDDialysed. Dose as in GFR<10 mL/ min
HDF/High fluxDialysed. Dose as in GFR<10 mL/ min
CAV/VVHDNot dialysed. Dose as in GFR=10– 20 mL/min

Hepatic Dose :

Immediate release injectables
Specific guidelines for dosage adjustments in hepatic impairment are not available. Adjust dosing as per clinical response.

Extended-release subcutaneous injections
Mild hepatic impairment: No dosage adjustments required.
Moderate to severe hepatic impairment: Use is contraindicated.

Sublingual dosage forms and buccal films
Mild to moderate hepatic impairment: Use is contraindicated.
Severe hepatic impairment: Start with a reduced dose and increase to 50% recommended dose.

Transdermal patch and subdermal implants
Consider the use of an alternate analgesic in patients with severe hepatic impairment.
03/20/2024 22:33:49 Buprenorphine
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0